Moderna (MRNA) Other financing activities (2018 - 2026)

Moderna (MRNA) has reported Other financing activities for 9 consecutive years, with $23.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other financing activities rose 64.29% year-over-year to $23.0 million in Q2 2026; TTM through Jun 2026 was $60.0 million, a 66.67% increase from a year earlier, with the FY2025 full-year figure at $35.0 million, down 46.97% from the prior year.
• Other financing activities was $23.0 million for Q2 2026 at Moderna, up from $19.0 million in the prior quarter.
• Over five years, Other financing activities peaked at $32.0 million in Q2 2024 and troughed at $2.0 million in Q3 2025.
• A 5-year average of $14.1 million and a median of $14.5 million in 2023 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities slumped 80.0% in 2025 and surged 533.33% in 2026, its largest moves.
• Over 5 years, Other financing activities stood at $25.0 million in 2022, then sank by 40.0% to $15.0 million in 2023, then dropped by 26.67% to $11.0 million in 2024, then surged by 45.45% to $16.0 million in 2025, then surged by 43.75% to $23.0 million in 2026.
• The last three Other financing activities figures came in at $23.0 million (Q2 2026), $19.0 million (Q1 2026), and $16.0 million (Q4 2025), per Business Quant data.